Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix–Targeted Radiopharmaceutical against Triple-Negative Breast Cancer

20260 citationsJournal Articlegreen Open Access

Authors

Justin S Hachey · Memorial Sloan Kettering Cancer Center

Tara Viray · Memorial Sloan Kettering Cancer Center

Sebastian E. Carrasco · Memorial Sloan Kettering Cancer Center

Lukas M. Carter · Memorial Sloan Kettering Cancer Center

Tullio V.F. Esposito · Memorial Sloan Kettering Cancer Center

Mattia Matasci · Philochem (Switzerland)

Domenico Ravazza

Abstract

The zirconium-89/lutetium-177 theranostic nuclide coupling with the F8 delivery vector successfully identified TNBC xenografts and significantly extended the survival of xenografted mice.

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Cell Adhesion Molecules Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 32, Issue 7, pp. 1337-1348

DOI: 10.1158/1078-0432.ccr-25-3354

Field-Weighted Citation Impact: 0.00